Cancer Immunotherapy, ADCs, Targeted Therapy & mRNA Vaccines

China crashes the cancer-vaccine race
Three Chinese teams put up clinical numbers at AACR 2026 that match what Moderna and Russia spent five years getting to.

For most of 2025, cancer-vaccine headlines came from three places: Moderna, BioNTech, and Gamaleya in Moscow. AACR 2026, which closed April 22 in San Diego, added a fourth address. RG002, a Chinese mRNA-LNP vaccine targeting HPV-16/18 E2/E6/E7, cleared every cervical lesion and every viral copy in twelve women with CIN2/3 within seventeen weeks of the first dose. Two days later Hangzhou Neoantigen Therapeutics reported that iNeo-Vac-P01 — a personalized peptide neoantigen vaccine — held three-year recurrence-free survival at 78.5% in 23 resected esophageal-cancer patients, against the 43% benchmark from the CheckMate 577 nivolumab arm.

A third Chinese paper, from Peking University, put EchoNeo 1.0 on top of the leaderboard for neoantigen prediction — beating DeepImmuno and IEDB on independent test sets. Three Chinese cancer-vaccine programs in one conference cycle, two of them already in patients. China's 15th Five-Year Plan named cell programming and synthetic biology as priorities in March, and the upstream IP for peptide synthesis and lipid nanoparticles is much thinner than for checkpoint inhibitors — the chokepoints that slowed China's last catch-up are largely absent here.

Gamaleya's Aleksandr Gintsburg used an April 25 Gazeta.ru interview to fill in NeoOncVac dosing details that Russian press had been carefully avoiding. The vaccine is given as ten intramuscular injections — weekly, then every three weeks — and the route changes with stage: into the tumor early, into the bloodstream once the cancer has spread. Gintsburg also said the program had cut metastases by roughly 90% in animal trials. No peer-reviewed paper supports that number. The first Russian human patient — a 60-year-old in Kursk — is on dose three of the regimen Gintsburg just described.

IO Biotech has been running IO102/IO103 in patients since 2018 — years ahead of both Moderna's mRNA-4359 and Evaxion's EVX-01. The peptide vaccine encodes the same two antigens as mRNA-4359, IDO and PD-L1. In its Phase 1/2 melanoma cohort, 80% of anti-PD-1-naive patients responded; at 45 months of follow-up, median progression-free survival sat at 25.5 months. The Phase III is fully enrolled at 407 patients. Moderna's 83% ORR in 12 first-line patients runs on biology that IO Biotech clinically validated half a decade earlier.

September brings Moderna's V940 Phase III readout in melanoma — the year's main pivot. BioNTech's autogene cevumeran is the second one to watch: at 3.2 years of follow-up, recurrence-free survival in immune responders still sits at 13.4 months, durable evidence that mRNA vaccines do something in pancreatic cancer, the tumor type that has resisted everything. The HHS $200M public-private fund is supposed to start placing money in adjuvant trials this summer, though RFK Jr. has pulled about $500M out of federal mRNA budgets elsewhere. By winter the field's question won't be whether mRNA cancer vaccines work. It will be which country's manufacturing infrastructure can run them at scale.